ArticleAdvanced healthcare materials2026
Lock-Open: An AND Logic-Gated, Entropy-Driven DNA Nanowalker for Highly Sensitive Detection of UDG and APE1 Activities in Hepatocellular Carcinoma.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Early diagnosis of HCC remains a clinical challenge, with survival strongly dependent on reliable biomarkers and translatable detection tools. Herein, we establish uracil-DNA glycosylase (UDG) and apurinic/apyrimidinic endonuclease 1 (APE1) as diagnostic biomarkers for early-stage HCC and develop a lock-open strategy based on an AND logic-gated, entropy-driven DNA nanowalker (ALEN) for highly sensitive detection of their enzymatic activities. ALEN integrates sequential UDG/APE1 processing with miR-21 gating to achieve on-track signal amplification. In the locked state, circuit leakage is minimized. Upon UDG/APE1 processing and miR-21 gating, ALEN is unlocked to initiate walker propagation, reactant regeneration, and spatially confined amplification selectively in tumor cells. This ability overcomes critical limitations of conventional entropy-driven DNA circuits, including low efficiency, limited turnover, and excessive leakage. When encapsulated in aptamer-functionalized lipid nanoparticles, ALEN gains robust biostability, biocompatibility, and HCC-specific accumulation. Using in vitro cellular models and in vivo mouse models of HCC, we confirmed that ALEN enables highly sensitive, cell type-specific discrimination of the activities of UDG and APE1, as well as timely and sensitive sensing of their dynamic fluctuations. Our results demonstrate that ALEN facilitates HCC diagnosis and monitoring of tumor progression, highlighting its promise as a clinical management tool.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.